Matthew W. Foehr
2018 - Ligand Pharmaceuticals
In 2018, Matthew W. Foehr earned a total compensation of $3.3M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 4% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $252,412 |
|---|---|
| Option Awards | $1,164,133 |
| Salary | $458,931 |
| Stock Awards | $1,361,147 |
| Other | $87,517 |
| Total | $3,324,140 |
Foehr received $1.4M in stock awards, accounting for 41% of the total pay in 2018.
Foehr also received $252.4K in non-equity incentive plan, $1.2M in option awards, $458.9K in salary and $87.5K in other compensation.
Rankings
In 2018, Matthew W. Foehr's compensation ranked 3,460th out of 14,244 executives tracked by ExecPay. In other words, Foehr earned more than 75.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,460 out of 14,244 | 76th |
Division Manufacturing | 1,279 out of 5,759 | 78th |
Major group Chemicals And Allied Products | 447 out of 2,122 | 79th |
Industry group Drugs | 368 out of 1,811 | 80th |
Industry Pharmaceutical Preparations | 281 out of 1,385 | 80th |
Source: SEC filing on April 24, 2020.
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2018.